SavedAdd your journal

Journals / Southern Clinics of Istanbul Eurasia / 2020 / Cilt: 31 - Sayı: 1

The Impacts of Baseline Retinal Volume on Visual Outcomes in the Treatment of Diabetic Macular Edema

Diyabetik Maküla Ödemi Tedavisinde Başlangıç Retina Hacminin Görsel Sonuç Üzerindeki Etkisi

Mehmet Giray ERSÖZ
Mümin HOCAOĞLU
Murat KARAÇORLU
Pages
50–53
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

At 12 months; VA was 67.4±11.6 letter; CRT was 410.2±124.2 μmand RV was 10.6±2.2 mm3 (p=0.001, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To assess the effects of initial retinal volume (RV) on visual acuity (VA) afterintravitreal bevacizumab treatment for diabetic macular edema (DME).Methods: The data of 28 eyes of 19 patients treated with bevacizumab for clinically signifi-cant diabetic macular edema were retrospectively evaluated in this study.
📊
Key Findings & Data:The associationof visual acuity and letter gain with initial retinal volüme (RV) and central retinal thickness(CRT) after one year of treatment were evaluated.Results: Baseline VA was 58.9±11.9 letters; CRT was 564.2±125.1 μm and baseline RVwas 12.4±2.3 mm3.
💡
Conclusion & Impact:At 12 months; VA was 67.4±11.6 letter; CRT was 410.2±124.2 μmand RV was 10.6±2.2 mm3 (p=0.001, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To assess the effects of initial retinal volume (RV) on visual acuity (VA) afterintravitreal bevacizumab treatment for diabetic macular edema (DME).Methods: The data of 28 eyes of 19 patients treated with bevacizumab for clinically signifi-cant diabetic macular edema were retrospectively evaluated in this study. The associationof visual acuity and letter gain with initial retinal volüme (RV) and central retinal thickness(CRT) after one year of treatment were evaluated.Results: Baseline VA was 58.9±11.9 letters; CRT was 564.2±125.1 μm and baseline RVwas 12.4±2.3 mm3. At 12 months; VA was 67.4±11.6 letter; CRT was 410.2±124.2 μmand RV was 10.6±2.2 mm3 (p=0.001, p

Özet

Amaç: Diyabetik maküla ödemi (DMÖ) nedeniyle intravitreal bevacizumab tedavisi uygulanan hastalarda başlangıç retina hacminin son görme keskinliği (GK) ve harf kazanımı (HK) ile ilişkisini araştırmak. Gereç ve Yöntem: Klinik olarak anlamlı DMÖ nedeniyle intravitreal bevacizumab enjeksiyonu yapılan 19 hastanın 28 gözü geriye dönük olarak incelendi. Spektral-domain optik koherens tomografi (SD-OKT) ile ölçülen başlangıç retina hacmi (RH) ve santral retinal kalınlığının (SRK) bir yıl sonundaki GK ve harf kazanımı ile ilişkisi incelendi. Bulgular: Başlangıç GK 58.9±11.9 harf, SRK 564.2±125.1 μm ve başlangıç RH 12.4±2.3 mm3 iken final GK 67.4±11.6 harf, SRK 410.2±124.2 μm ve final RH 10.6±2.2 mm3 idi (sırasıyala, p=0.001, p

🔖

Cite This Article

ERSÖZ, M. G., HOCAOĞLU, M., KARAÇORLU, M. (2022). The Impacts of Baseline Retinal Volume on Visual Outcomes in the Treatment of Diabetic Macular Edema. Southern Clinics of Istanbul Eurasia, Cilt: 31 - Sayı: 1, 50–53. https://ajindex.com/articles/592818

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Wang W, Lo ACY. Diabetic Retinopathy: Pathophysiology and Treatments. Int J Mol Sci 2018;19:E1816
  2. Liu Y, Yang J, Tao L, Lv H, Jiang X, Zhang M, et al. Risk factors of diabetic retinopathy and sight-threatening diabetic retinopathy: a cross-sectional study of 13 473 patients with type 2 diabetes mellitus in mainland China. BMJ Open 2017;7:e016280
  3. Nentwich MM, Ulbig MW. Diabetic retinopathy - ocular complications of diabetes mellitus. World J Diabetes 2015;6:489–99
  4. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998;105:998–1003
  5. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86
  6. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796–806
  7. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopaty and tumors. J Biol Chem 1999;274:23463–7
  8. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117:1078–86
  9. Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011;118:1819–26
  10. Göker YŞ, Tekin K, Kızıltoprak H, Üçgül Atılgan C, Kosekahya P. Bevacizumab Therapy For Diabetic Macular Edema: A Real Life Study. Dicle Med J 2019;46:235–40
  11. Oruç Dündar S, Çakmak H. Place of ANTI-VEGF in Diabetic Macular Edema. Ret-Vit Özel Sayı 2015;23:43–9
  12. Batıoğlu F. Ranibizumab Monotherapy in Diabetic Macular Edema. Turkiye Klinikleri J Ophthalmol-Special Topics 2013;6:61–6
  13. Bardak Y. Bevacizumab Monotheraphy in Diabetic Macular Edema. Turkiye Klinikleri J Ophthalmol-Special Topics 2013;6:67–70
  14. Soheilian M, Ramezani A, Yaseri M, Mirdehghan SA, Obudi A, Bijanza